Table 1 Clinico-pathological features of the assessed AML patients
Patients’ characteristics | Frequency (%) |
|---|---|
Age (median and range), years | 33 (18–65) |
TLC (median and range), × 109/L | 38.9 (1–440) |
HB (median and range), g/dl | 8 (5.5–13) |
Sex | |
Male | 50 (54.9) |
Female | 41 (45.1) |
BM cellularity | |
Hypercellular | 70 (76.9) |
Hypocellular | 7 (7.7) |
Normocellular | 14 (15.4) |
FAB classification | |
M1 | 11 (12.1) |
M2 | 38 (41.8) |
M4 | 24 (26.4) |
M5 | 17 (18.7) |
M7 | 1 (1.1) |
Organomegally | |
Hepatomegaly | 27 (29.7) |
Spleenomegaly | 23 (25.3) |
CD34 | |
Negative | 27 (29.7) |
Positive | 64 (70.3) |
CD13 | |
Positive | 91 (100) |
CD117 | |
Negative | 19 (20.9) |
Positive | 72 (79.1) |
CD14 | |
Negative | 47 (51.6) |
Positive | 44 (48.4) |
Aberrant IPT markers | |
Without aberrant marker | 73 (80.2) |
With aberrant marker | 18 (19.8) |
Response to treatment | |
CR | 68 (74.7) |
No CR | 23 (25.3) |
PLT (median and range)×109/L | 35 (5–297) |
BP blast (median and range) % | 50 (0–98) |
BM blast (median and range) % | 70 (14–97) |
CD4 | |
Negative | 54 (59.3) |
Positive | 37 (40.7) |
Cytogenetic risk | |
Favorable | 18 (19.8) |
Intermediate | 51 (56.0) |
Unfavorable | 22 (24.2) |
IPT | |
Mono | 7 (8.0) |
Myelo | 50 (57.5) |
Myelomono | 29 (33.3) |
Megakaryoblastic | 1 (1.1) |
Lymphadenopathy | |
Negative | 61 (67.0) |
Positive | 30 (33.0) |
MPO | |
Negative | 3 (3.3) |
Positive | 88 (96.7) |
CD33 | |
Positive | 91 (100) |
HLA/DR | |
Negative | 16 (17.6) |
Positive | 75 (82.4) |
CD11c | |
Negative | 52 (57.1) |
Positive | 39 (42.9) |
FLT3 (ITD) | |
Wild | 77 (84.6) |
Mutant | 14 (15.4) |
Death | |
Alive | 37 (40.7) |
Dead | 54 (59.3) |